Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Galectin-12
- Target
- Galectin-12
- Molecular classification
- Lectin (β-galactoside-binding protein), Tandem-repeat type galectin (two CRDs linked by a peptide), Intracellular protein primarily associated with lipid droplets
01
Overview
Galectin-12 is a tandem-repeat galectin (lectin family) protein with two carbohydrate-recognition domains, mostly found on lipid droplets in adipocytes. It regulates lipid degradation via modulation of protein kinase A signaling, influences cell differentiation and apoptosis, inhibits macrophage polarization to the M2 population (promoting inflammation), and has been implicated in metabolic syndrome, insulin resistance, and adipocyte biology. Galectin-12 differs from other galectins in the sequence and carbohydrate-binding capacities of its CRDs, and its expression is highly specific to fat tissue. The protein may serve as a metabolic regulator and potential therapeutic target for obesity, diabetes, and related inflammatory conditions
- Other names
- Lgals12 (gene symbol)
02
Mechanism of action
Not established for drugs since no specific galectin-12-targeted therapeutics exist. Potential mechanisms include modulation of galectin-12 to alter adipogenesis, lipolysis, apoptosis, or immune polarization.
03
Biological functions
Adipogenesis (regulates adipocyte differentiation)Apoptosis (induces cell death under certain conditions)Cell cycle arrest (G1 phase)Regulation of lipolysis (modulates PKA signaling and lipid metabolism)Immune modulation (inhibits macrophage M2 polarization, thereby influencing inflammation)Cellular energy homeostasis
04
Disease associations
Metabolic syndromeInsulin resistance / type 2 diabetesObesityInflammationCancer (role in myeloid differentiation and chemotherapy resistance)
05
Safety considerations
Modulation of galectin-12 could potentially affect energy metabolism, immune responses, and cell viability, but specific safety concerns for therapeutic targeting are not established due to lack of clinical drugs
06
Interacting drugs
Currently, no specific approved drugs directly targeting galectin-12. Research is ongoing to develop modulators, but none are clinically established.
07
Biomarkers
Expression of galectin-12 in adipose tissue may serve as a biomarker for insulin sensitivity or obesity-related metabolic dysfunction
Beyond the preview
Go deeper on Galectin-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Galectin-12.